Fate Therapeutics Announces Oral Presentation on Natural Killer Cell Product Candidate FATE-NK100 at the 2016 ASH Annual Meeting

SAN DIEGO, Nov. 03, 2016 -- Fate Therapeutics, Inc. (NASDAQ:FATE), a biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, announced today that six abstracts highlighting the Company’s programs, including an oral presentation on its natural killer (NK) cell product candidate FATE-NK100 as well as multiple poster presentations on its off-the-shelf cancer immunotherapy pipeline, have been accepted for presentation at the 58^th American Society of Hematology (ASH) Annual Meeting and Exposition. The meeting will be held December 3-6, 2016 in San Diego.

ASH Presentations on Fate Therapeutics’ Programs

FATE-NK100:
TITLE: Development and Scale-up of a Novel GMP Method for Enrichment and Expansion of Terminally Differentiated Adaptive Natural Killer Cells (FATE-NK100) with Enhanced Anti-Tumor Function 
Frank Cichocki  
Publication Number: 1225 
Session Name: 711. Cell Collection and Processing: Immunotherapy, Immunomodulation, and Immune Reconstitution 
Date and Time: Monday, December 5, 2016, 6:15 PM 
Room: San Diego Convention Center, Room 30

Off-the-Shelf Cancer Immunotherapy:
TITLE: Off-the-Shelf Natural Killer Cell Immunotherapy for Enhanced Antibody Directed Cellular Cytotoxicity
Ryan Bjordahl
Publication Number:  3363
Session Name: 703. Adoptive Immunotherapy: Poster II
Date and Time: Sunday, December 4, 2016, 6:00 PM – 8:00 PM
Location: San Diego Convention Center, Hall GH

TITLE: Genetically Enhanced Pluripotent Stem Cell-Derived T Lymphocytes for Off-the-Shelf Cellular Immunotherapy
Raedun Clarke
Publication Number: 2164
Session Name: 703. Adoptive Immunotherapy: Poster I
Date and Time: Saturday, December 3, 2016, 5:30 PM - 7:30 PM
Location: San Diego Convention Center, Hall GH

TITLE: Genetic Engineering of Pluripotent Cells for the Continuous Derivation of Off-the-Shelf Effector Lymphocytes with Enhanced Therapeutic Persistence by Overcoming the Host Histocompatibility Barrier
Raedun Clarke
Publication Number: 2165
Session Name: 703. Adoptive Immunotherapy: Poster I
Date and Time: Saturday, December 3, 2016, 5:30 PM - 7:30 PM
Location: San Diego Convention Center, Hall GH

Collaboration with Juno Therapeutics:
TITLE: Identification of Small Molecule Modulators to Enhance the Therapeutic Properties of Chimeric Antigen Receptor T Cells
Jonathan Rosen
Publication Number: 4712
Session Name: 802. Chemical Biology and Experimental Therapeutics: Poster III
Date and Time: Monday, December 5, 2016, 6:00 PM - 8:00 PM
Location: San Diego Convention Center, Hall GH

ProTmune™:
TITLE: Economic Burden of Acute Graft-Versus-Host Disease (GvHD) Following Allogeneic Hematopoietic Cell Transplant (HCT) for Hematologic Malignancies
Walter Grubb
Publication Number: 1187
Session Name: 902. Health Services Research—Malignant Conditions: At the Corner of Cost and Efficacy
Date and Time: Monday, December 5, 2016, 5:30 PM
Room: San Diego Convention Center, Room 28 A-D

About Fate Therapeutics, Inc.
Fate Therapeutics is a biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders. The Company’s hematopoietic cell therapy pipeline is comprised of NK- and T-cell immuno-oncology programs, including off-the-shelf product candidates derived from engineered induced pluripotent cells, and immuno-regulatory programs, including product candidates to prevent life-threatening complications in patients undergoing hematopoietic cell transplantation and to promote immune tolerance in patients with autoimmune disease. Its adoptive cell therapy programs are based on the Company’s novel ex vivo cell programming approach, which it applies to modulate the therapeutic function and direct the fate of immune cells. Fate Therapeutics is headquartered in San Diego, CA. For more information, please visit www.fatetherapeutics.com.

Contact:
Christina Tartaglia
Stern Investor Relations, Inc.
212.362.1200
[email protected]